5995-86-8
Chemical Structure
Gallic acid hydrate
Synonym(s): 3,4,5-Trihydroxybenzoic acid hydrate
- CAS. Nr.: 5995-86-8
- Formula:C7H8O6
- Molecular Weight:188.13
IUPAC Name: 3,4,5-trihydroxybenzoic acid hydrate
InChIKey: IUTKPPDDLYYMBE-UHFFFAOYSA-N
SMILES: O=C(O)C1=CC(O)=C(O)C(O)=C1.O
Biological Activity: Gallic acid (3,4,5-Trihydroxybenzoic acid) hydrate is a natural polyhydroxyphenolic compound and an free radical scavenger to inhibit cyclooxygenase-2 (COX-2)[1]. Gallic acid hydrate has various activities, such as antimicrobial, antioxidant, antimicrobial, anti-inflammatory, and anticance activities[2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Gallic acid hydrate | 98.87% | Gallic acid (3,4,5-Trihydroxybenzoic acid) hydrate is a natural polyhydroxyphenolic compound and an free radical scavenger to inhibit cyclooxygenase-2 (COX-2). Gallic acid hydrate has various activities, such as antimicrobial, antioxidant, antimicrobial, anti-inflammatory, and anticance activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Gallic acid hydrate (Standard) | 99.86% | Gallic acid (hydrate) (Standard) is the analytical standard of Gallic acid (hydrate). This product is intended for research and analytical applications. Gallic acid (3,4,5-Trihydroxybenzoic acid) hydrate is a natural polyhydroxyphenolic compound and an free radical scavenger to inhibit cyclooxygenase-2 (COX-2). Gallic acid hydrate has various activities, such as antimicrobial, antioxidant, antimicrobial, anti-inflammatory, and anticance activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Amaravani M, et al. COX-2 structural analysis and docking studies with gallic acid structural analogues. Springerplus. 2012 Dec;1(1):58. [Content Brief]
- [2]. Bak EJ, et al. Gallic acid improves glucose tolerance and triglyceride concentration in diet-induced obesity mice. Scand J Clin Lab Invest. 2013 Dec;73(8):607-14. [Content Brief]